A randomized phase II study of TS-1+Cisplatin versus Vinorelbine+Cisplatin,with thoracic radiotherapy for locally advanced non-small cell lung cancer.
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000002420
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Not provided
Exclusion Criteria
-T3N1 -SVC syndrome. -Clinically significant pleural or pericardial effusion,Contralateral Hilar lymph node metastasis, -Patients with concurrent serious infections or complications -Continuous watery diarrhea -Paralysis of the intestine, or ileus -Significant interstitial pneumonitis ,pulmonary fibrosis or severe emphysema in Chest Xp -The presence of other concomitant cancers -Concomitant therapy with another new anticancer drug, phenytoin, warfarin or flucytocine -Inadequately controlled diabetes mellitus -HBs Ag is positive -A history of serious drug allergy -Mental disease or psychotic manifestation -Pregnancy,breast feeding or wish of future bearing -Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 year survival rate
- Secondary Outcome Measures
Name Time Method Over all survival, Progression free survival, Compliance rate of protocol regimen, Adverse event